Table 28.

Registered treatments that are not reimbursed

Treatment	Countries where reimbursement is not offered for osteoporosis*
Risedronate	Malta
Alendronate	Malta, Slovakia
Ibandronate	Cyprus, Malta
Zoledronate	Bulgaria, Ireland, Malta, Poland
Raloxifene	Czech Republic, Estonia, Finland, Hungary, Latvia, Lithuania, Malta, Poland
Denosumab	Cyprus, Ireland, Malta
Strontium Ranelate	Only markets with reimbursement: Cyprus, Italy, Lithuania, the Netherlands, Romania, Spain, UK [removed from several markets]
Teriparatide and PTH	Estonia, Ireland, Latvia, Malta, Poland, Romania
Alfacalcidol/calcitriol/calcidiol	Finland, Ireland, Lithuania, Malta, Poland, Romania

*Data for Luxembourg not reported